安德罗格拉福利德通过AKT信号通路逆转KBChR 8-5细胞中的多药性耐药性
Deepa S Lakra1, Pradhapsingh Bharathiraja1, T Dhanalakshmi1,2
1Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu, India.
Cell biochemistry and function
|February 21, 2024
概括
安德罗格拉福利德 (Andro) 通过提高化疗效果,逆转癌细胞中的多药性耐药性 (MDR). 这种天然化合物通过ABCB1/AKT通路对抗药细胞产生敏感性,从而提供了新的治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 多种药物耐药性 (MDR) 是癌症化疗中的一个重大挑战.
- 基蛋白 (P-gp) 是一种ATP结合盒 (ABC) 载体,是MDR的一个关键媒介.
- 耐药癌细胞系,如KBChR 8-5,对于研究MDR逆转策略至关重要.
研究的目的:
- 为了研究andrographolide (Andro) 的MDR敏感化特性.
- 评估Andro在KBChR 8-5细胞中逆转P-糖蛋白介导的MDR的能力.
- 探索Andro作用的潜在分子机制.
主要方法:
- 在P-gp过度表达KBChR 8-5细胞中评估Andro的细胞毒性.
- 评估安德罗和化疗药物 (PTX,DOX) 之间的协同作用.
- 测量反应性氧物种 (ROS) 水平,线粒体膜潜力 (MMP) 和细胞周期进展.
- 分析了ABCB1,AKT,caspase 3和caspase 9的表达.
主要成果:
- 安德罗在耐药细胞中表现出剂量依赖的细胞毒性和与PTX和DOX的协同效应.
- 用Andro的联合治疗提高了ROS,降低了MMP,并诱导了细胞循环停止.
- 安德罗治疗降低了ABCB1和AKT的表达.
- 安德罗增强了酶3和酶9的表达,促进了亡.
结论:
- 安德罗格拉福利德有效地逆转KBChR 8-5细胞中的P-gp介导的多药性耐药性.
- 这种MDR逆转机制涉及到ABCB1/AKT信号通路的调节.
- 安德罗具有作为提高癌症化疗结果的敏感剂的潜力.
关键词:
在AKT信号传输中.这是一种P-glycoprotein蛋白.安德罗格拉福利德 (andrographolide) 是一种灭症 (apoptosis) 是一种死亡的过程.多种药物耐药性多种药物耐药性更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
